Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Carboplatin in Unresectable Pleural Malignant Mesothelioma: NCT03920839 Clinical Landscape Report 2026
16 October 2026
NCT03920839 clinical landscape for Unresectable Pleural Malignant Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
(-)-Epigallocatechin Gallate in Idiopathic Pulmonary Fibrosis: NCT03928847 Clinical Landscape Report 2026
16 October 2026
NCT03928847 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HBI-002 in Anemia, Sickle Cell: NCT03926819 Clinical Landscape Report 2026
16 October 2026
NCT03926819 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bone Marrow-Derived Mesenchymal Stem Cells(Mayo Clinic) in Connective Tissue Diseases: NCT03929120 Clinical Landscape Report 2026
16 October 2026
NCT03929120 clinical landscape for Connective Tissue Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydromorphone Hydrochloride in Vaso-occlusive crisis: NCT03933397 Clinical Landscape Report 2026
16 October 2026
NCT03933397 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eptacog alfa biosimilar (Aryogen) in Hemophilia B: NCT03935334 Clinical Landscape Report 2026
16 October 2026
NCT03935334 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Sarcoma: NCT03935893 Clinical Landscape Report 2026
16 October 2026
NCT03935893 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Canakinumab in Muscular Dystrophy, Duchenne: NCT03936894 Clinical Landscape Report 2026
16 October 2026
NCT03936894 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pirfenidone in Idiopathic Pulmonary Fibrosis: NCT03939520 Clinical Landscape Report 2026
16 October 2026
NCT03939520 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Marstacimab-hncq in Hemophilia B: NCT03938792 Clinical Landscape Report 2026
16 October 2026
NCT03938792 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tramadol Hydrochloride in Anemia, Sickle Cell: CTRI/2019/05/019359 Clinical Landscape Report 2026
16 October 2026
CTRI/2019/05/019359 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant coagulation factor VIII ( Sino Cell Technologies) in Hemophilia A: NCT03947320 Clinical Landscape Report 2026
16 October 2026
NCT03947320 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.